Just a few weeks after Dexcom’s Stelo became the first over-the-counter continuous glucose monitor (CGM) to be approved by the FDA, Abbott has got the green light for its Lingo device - and ...

Abbott Laboratories (ABT.N), opens new tab on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects new device launches and growing demand for its glucose ...

In March 2024, the FDA approved the first over-the-counter continuous glucose monitors (CGMs ... That’s where over-the-counter devices, like Abbott’s Lingo, come in – empowering anyone ...

In June 2024, FDA cleared Abbott’s Lingo. The monitors cost from $83 to $99 per month out-of-pocket, depending on how many devices are purchased. Other versions of continuous glucose monitors ...